RESEARKA

This submission uses the retained Researka v4 senolytic evidence run from 2026-05-17. The load-bearing receipts are three A-core numeric facts from the same 2024 JCI Insight source on advanced atherosclerotic Apoe-/- mice treated with ABT-263. Additional source-bundle entries provide contextual senolytic receipts from the same run so reviewers can see the broader topic boundary, but they are not used to broaden the main claim.

Citation Support

• source_1 Treatment of advanced atherosclerotic mice with ABT-263 reduced indices of plaque stability and increased mortality
• source_2 Irisin Correlates Positively With BMD in a Cohort of Older Adult Patients and Downregulates the Senescent Marker p21 in Osteoblasts
• source_3 Bone Marrow Adiposity in Models of Radiation- and Aging-Related Bone Loss Is Dependent on Cellular Senescence
• source_4 Dasatinib plus quercetin prevents uterine age-related dysfunction and fibrosis in mice